See other companies on Welcome to the Jungle
InterVenn
Technology stack for precision medicine
- 101-200 employees
- Healthcare
- B2B
- Science
- Downtown, South San Francisco, CA
Jump to section
Company mission
To create a world where no one is ever blindsided by disease.
Our take
Glycoproteomics is an emerging life science field that helps improve biomarker and target discovery, but existing practices are time-consuming. The process yields a huge body of data within minutes, but the analysis of this data can take months and is generally impossible to reproduce due to inconsistent methodology.
InterVenn supplies an AI platform for mass spectrometry which significantly increases the speed and efficiency of glycoproteomics data analysis. This is achieved by applying machine learning to the hi-res characterization of post-translational modifications. What's more, Intervenn’s process aims to be consistent thus reducing workflow variability and improving the chances of reproducing the process.
The startup presents valuable opportunities for the innovation of the glycoproteomics field by focusing on optimizing workflows, which should in turn increase the research rate in the field. The company recently updated its senior management as it looks to accelerate its development as a commercial company, building out its team with professionals experienced in driving novel precision diagnostics and medicines to market.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Employee Assistance Program
- Paid Holidays
- Last Week of December
- Pet Insurance
- On-Site Gym / Fitness Classes
- Health / Dental / Vision
- Unlimited Time Off
- Hybrid/Remote Work Opportunities
- Company Outings
- Commuter Benefits Program
- Weekly Catered Meals
- Holiday Events
- Flexible Work Hours
- Casual Dress
- Snacks
- Work-From-Home Stipend
- Employee Resource Group
Company values
- Scientific data and integrity
- Radical transparency
- Clarity in thought, communication and mission
- Enjoyment and innovative curiosity
- Extreme responsibility
Funding (last 2 of 3 rounds)
Aug 2021
$201m
SERIES C
Nov 2020
$34m
SERIES B
Total funding: $244.4m
This company has top investors
Leadership
Aldo Carrascoso
(Co-founder)Former CEO of the company. Also co-founded Veem and Jukin Media, where they have worked in COO and CTO roles.
Carolyn Bertozzi
(Co-founder)Nobel Laureate and Professor at Stanford University. Member of the National Academies of Sciences, Medicine, and Inventors.
Carlito Lebrilla
(Co-founder)Distinguished Professor at UC Davis. Fellow of the American Academy for the Advancement of Science.